The ORBITA (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) trial has created frequent and heated debate among interventionalists and cardiologists and has been a source significant negative press in the news media over the past 10 months. Has any of that affected your practice? What, if any, impact have these data and public debate had on your volume of percutaneous coronary interventions (PCI)?

Clinical Topics: Invasive Cardiovascular Angiography and Intervention, Stable Ischemic Heart Disease, Atherosclerotic Disease (CAD/PAD), Interventions and Coronary Artery Disease, Chronic Angina

Keywords: Angioplasty, Angina, Stable, Coronary Artery Disease

< Back to Listings